RxDoctor Payments DataLook up a doctor →

Sara Everman, PA

Physician Assistant · Ashland, KYNPI 1851669048

Payments from drug & device makers

$11,182in general payments, 2019–2025

Across 777 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • AbbVie$1K
  • Johnson & Johnson$878
  • Ardelyx, Inc.$465
  • Takeda Pharmaceuticals U.S.A., Inc.$438
  • Redhill Biopharma Inc.$422
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$11,08699%
  • Education$761%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,182 in reported general payments places this provider in the 95th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$77,845
Medicare patients
593
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase73$224,739
XifaxanRifaximin53$147,633
LinzessLinaclotide117$122,197
IbsrelaTenapanor Hcl35$74,997
RelistorMethylnaltrexone Bromide15$64,356
RemicadeInfliximab12$64,007
ZenpepLipase/Protease/Amylase15$53,544
TrulancePlecanatide35$42,437
Mesalamine ErMesalamine91$29,587
Mesalamine44$25,671
Dexlansoprazole DrDexlansoprazole83$23,148
Sucralfate342$22,458
VoqueznaVonoprazan Fumarate12$14,447
Famotidine769$12,141
Pantoprazole Sodium988$12,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,324$346,936190 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance$4,378$254,425103 claims
Ardelyx, Inc.Ibsrela$465$74,99735 claims
Johnson & JohnsonRemicade$878$64,00712 claims
Aimmune Therapeutics, Inc.Zenpep$181$53,54415 claims
Phathom Pharmaceuticals, Inc.Voquezna$200$14,44712 claims
Redhill Biopharma Inc.Movantik$422$4,98513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →